“…[23,24,27,28] Moreover, the risk factors for visual field loss are poorly understood, although a higher frequency has been reported in association with male gender, [8,11,12,15,29] concomitant treatment with other antiepileptic drugs (AEDs), [30] higher cumulative dose of vigabatrin [10,24,29,31] and longer duration of vigabatrin therapy. [10,29,31] We have previously reported the interim results of a large, observational, multicentre study designed to determine the frequency of, and the risk factors for, VAVFL in patients with refractory partial epilepsy, stratified by age (8-12 years of age, >12 years of age) treated with vigabatrin.…”